



# Evidence of impaired mitochondrial cellular bioenergetics in ocular fibroblasts derived from glaucoma patients

Neeru A. Vallabh<sup>a,b</sup>, Jane Armstrong<sup>c</sup>, Gabriela Czanner<sup>d,e</sup>, Brian McDonagh<sup>f</sup>,  
Anshoo Choudhary<sup>b</sup>, David N. Criddle<sup>c</sup>, Colin E. Willoughby<sup>a,g,\*</sup>

<sup>a</sup> Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L69 3BX, United Kingdom

<sup>b</sup> St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, United Kingdom

<sup>c</sup> Institute of Systems, Molecular and Integrative Biology, Biosciences Building, University of Liverpool, Liverpool, L69 7BE, United Kingdom

<sup>d</sup> School of Computer Science and Mathematics, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom

<sup>e</sup> Faculty of Informatics and Information Technology, Slovak University of Technology, 842 16, Bratislava, Slovakia

<sup>f</sup> Discipline of Physiology, School of Medicine, National University of Ireland, Galway, Ireland

<sup>g</sup> Genomic Medicine, Biomedical Sciences Research Institute, Ulster University, Coleraine, BT52 1SA, United Kingdom

## ARTICLE INFO

### Keywords:

Tenon's fibroblast  
Glaucoma  
Mitochondria  
Seahorse XF analyser  
Oxidative stress  
Bioenergetics

## ABSTRACT

Glaucoma is a progressive optic neuropathy characterized by the neurodegeneration of the retinal ganglion cells (RGCs) resulting in irreversible visual impairment and eventual blindness. RGCs are extremely susceptible to mitochondrial compromise due to their marked bioenergetic requirements and morphology. There is increasing interest in therapies targeting mitochondrial health as a method of preventing visual loss in managing glaucoma. The bioenergetic profile of Tenon's ocular fibroblasts from glaucoma patients and controls was investigated using the Seahorse XF24 analyser. Impaired mitochondrial cellular bioenergetics was detected in glaucomatous ocular fibroblasts including basal respiration, maximal respiration and spare capacity. Spare respiratory capacity levels reflect mitochondrial bio-energetic adaptability in response to pathophysiological stress. Basal oxidative stress was elevated in glaucomatous Tenon's ocular fibroblasts and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) induced reactive oxygen species (ROS) simulated the glaucomatous condition in normal Tenon's ocular fibroblasts. This work supports the role of therapeutic interventions to target oxidative stress or provide mitochondrial energetic support in glaucoma.

## 1. Introduction

Glaucoma is a progressive optic neuropathy characterized by the neurodegeneration of the retinal ganglion cells (RGCs) resulting in irreversible visual impairment and eventual blindness [1]. In glaucoma, damage and degeneration of RGCs and their axons result in characteristic changes in the appearance of the optic nerve head and patterns of visual field loss [2]. Glaucoma is the leading cause of irreversible blindness worldwide and is estimated to affect over 60 million people globally of which approximately 10% are estimated to be blind from this disease [3]. Glaucoma is an umbrella term for a heterogeneous group of optic neuropathies of which primary open angle glaucoma (POAG) is the most prevalent [4]. The pathogenesis of POAG is multifactorial and complex [5,6] but currently lowering intra-ocular pressure (IOP)

medically or surgically is the only modifiable risk factor [7]. POAG can be clinically sub-divided into patients with normal IOP, termed normal-tension glaucoma, and those with raised IOP, termed high-tension glaucoma [2,4]. Given that POAG can develop with a normal IOP, and even when IOP is adequately treated and controlled POAG patients can still progress to blindness [8–10], supports the concept that other non-IOP mechanisms can drive glaucoma development and progression.

Increased chronological age is an independent risk factor for glaucoma [11–14] and mitochondrial dysfunction is associated with age-related neurodegenerations [15]. RGCs are particularly susceptible to mitochondria dysfunction due to their high energy demands and unique morphology [16–18]. In the human glaucomatous retina, the RGC dendrites show early degeneration with remodelling and redistribution of the mitochondria, and a reduction in mitochondrial volume

\* Corresponding author. Genomic Medicine, Biomedical Sciences Research Institute, Ulster University, Coleraine Campus, Cromore Road, Coleraine, Northern Ireland, BT52 1SA, United Kingdom.

E-mail address: [c.willoughby@ulster.ac.uk](mailto:c.willoughby@ulster.ac.uk) (C.E. Willoughby).

<https://doi.org/10.1016/j.freeradbiomed.2022.07.009>

Received 17 April 2022; Received in revised form 29 June 2022; Accepted 12 July 2022

Available online 22 July 2022

0891-5849/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Abbreviations

RGCs	Retinal ganglion cells
POAG	primary open angle glaucoma
IOP	intraocular pressure
LHON	Leber's Hereditary Optic Neuropathy
ADOA	Autosomal Dominant Optic Atrophy
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide,
ROS	reactive oxygen species
GSS2	glaucoma staging system 2
TFs	Tenon's fibroblasts
GTFs	Glaucomatous Tenon's fibroblasts
NTFs	non-glaucomatous controls
DMEM	Dulbecco's Modified Eagle's Medium
PBS	phosphate buffered saline,
SEM	standard error of the mean
OCR	oxygen consumption rate
DMSO	Dimethyl sulfoxide,
mtDNA	mitochondrial DNA

[19]. This mirrors glaucomatous degeneration in animal models in which RGCs are under metabolic stress [20,21]. Inherited optic neuropathies like Leber's Hereditary Optic Neuropathy (LHON) and Autosomal Dominant Optic Atrophy (ADOA) result from mitochondrial mutations or nuclear gene mutations encoding mitochondrial proteins [22]. Vision is lost in both LHON and DOA due to RGC death secondary to mitochondrial dysfunction [22,23]. Due to the phenotypic similarities of these inherited optic neuropathies with glaucomatous optic neuropathy there has been increasing investigation of mitochondrial involvement in the pathogenesis of glaucoma [16,24–28]. Our group and others have reported mitochondrial DNA mutations in peripheral blood leucocytes from POAG patients [29–31]. Furthermore, defects in complex I oxidative phosphorylation and subsequent decreased mitochondrial respiration and ATP production have been detected in blood lymphocytes from POAG patients [23,32].

Cells derived from ocular tissues better represent the glaucomatous disease context and can be derived during ocular surgery [33,34] or from post-mortem studies [19,25]. Post-mortem studies are limited, expensive and challenging to obtain clinical data but have identified mitochondrial defects in the glaucomatous retina [19] and lamina cribrosa cells [25]. Mitochondrial dysfunction and autophagy have also been studied in glaucoma using Tenon's ocular fibroblasts [35]. Cataract surgery is an ocular procedure commonly performed in patients with and without glaucoma and allows the relatively simple harvesting of Tenon's ocular fibroblasts [36].

Herein, we report impaired mitochondrial cellular bioenergetics in Tenon's ocular fibroblasts derived from glaucoma (POAG) patients. Basal oxidative stress was elevated in glaucomatous Tenon's ocular fibroblasts and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) induced reactive oxygen species (ROS) simulated the glaucomatous condition in normal Tenon's ocular fibroblasts. This work supports the role of therapeutic interventions to target oxidative stress or provide mitochondrial energetic support in glaucoma.

## 2. Methods

### 2.1. Subjects and clinical assessment

Participants with primary open angle glaucoma (POAG) and disease negative non-glaucomatous controls were recruited at the Royal Liverpool University Hospital, Liverpool, U.K. This study adhered to the tenets of Declaration of Helsinki and were approved by the relevant institutions, with all participants giving informed written consent.

Ethical approval for the study was acquired from the NHS Research Ethics Committee (REC Ref 14/LO/1088). Clinical phenotyping included a detailed ocular and medical history, drug history, intraocular pressure (IOP) measurement by Goldmann tonometry, slit-lamp bio-microscopy with stereoscopic disc examination and gonioscopy, and visual field testing (Humphrey Visual Field Analyzer, Zeiss; Swedish interactive algorithm standard 24-2 program). The diagnosis of POAG was based on open anterior chamber angles on gonioscopy, glaucomatous optic nerve damage on funduscopy and a glaucomatous visual field defect. Glaucoma severity was graded by analysis of the visual field using the Glaucoma Staging System (GSS2) staging system [37]: mild (stage 0–1), moderate (stage 2–3), advanced (stage 4–5). Patients were excluded if below 18 years of age, if they had previous intraocular surgery or any findings on examination suggesting ocular hypertension or a secondary cause of glaucoma. Ethnically matched and age matched controls without glaucomatous optic neuropathy and a pressure less than 21 mmHg, were also recruited to the study.

### 2.2. Isolation of human primary Tenon's ocular fibroblasts

Human primary Tenon's ocular fibroblasts (TFs) were cultured from subjects with POAG (GTFs) or non-glaucomatous controls (NTFs) undergoing glaucoma or cataract surgery using the explant method as previously described [38]. A limbal incision was created as a part of glaucoma surgery (or at the site of sub-Tenon's injection of local anaesthetic after administration of topical anaesthetic for cataract surgery) and a 5 mm × 5 mm square of Tenon's tissue was excised from beneath the conjunctiva after separation by blunt dissection. Petri dishes were scored with blade with a middle 'X' and the Tenon's tissue explant was mechanically applied into this central 'X'. TFs were cultured in complete medium (Dulbecco's Modified Eagle's Medium/Nutrient Ham F12 (1:1) medium: DMEM/F12) supplemented with L-glutamine, 10% fetal calf serum, penicillin/streptomycin mix (1:1) and amphotericin (all from Sigma-Aldrich, UK). 5 ml of complete medium was applied and incubated at 37 °C with 5% CO<sub>2</sub> and 95% humidity in an incubator (Sanyo CO<sub>2</sub> Incubator MCO-17A, Sanyo, Japan) and cells were passaged until they reached passage 4. The cells were tested for mycoplasma using previously described techniques [39] and then used for further experiments or conserved at –80°C using 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, UK) until further use. Vimentin (V9) mouse monoclonal antibody (MA5 11,883) (ThermoFisher Scientific, USA) immunocytochemical staining (2 µg/ml in 1% BSA for 1 h at 37°C) was performed to confirm that the cells were fibroblasts.

### 2.3. Measurement of mitochondrial content

Citrate synthase activity was used as a quantitative marker of mitochondrial content in TFs. Intact mitochondria were isolated from TFs using a commercial Mitochondrial Isolation Kit (Thermoscientific, USA) from a Citrate Synthase Activity Assay (Sigma-Aldrich, USA). Citrate synthase activity is reported as nmole/min/mL = milliunit/mL. One unit of citrate synthase is the amount of enzyme that generates 1.0 mmol of CoA per minute at 25 °C and pH 7.2. Tenon's ocular fibroblasts from subjects with POAG (GTFs; n = 5) or non-glaucomatous controls (NTFs; n = 5) were tested in duplicate and citrate synthase activity assay analysed. Statistical significance was determined using unpaired t testing.

### 2.4. Seahorse XF24 analyzer measurement of cellular bioenergetics

Cellular bioenergetics of human primary Tenon's ocular fibroblasts (TFs) was determined using the extracellular flux analyser (Seahorse XF24 Analyzer; Seahorse Bioscience, Agilent Technologies, UK). TFs (2 × 10<sup>4</sup>) were seeded in a 24 well Seahorse XF plate and incubated at 37 °C with 5% CO<sub>2</sub> and 95% humidity for 24 h. Prior to the experiment the medium was removed from the cells and incubated for 1 h with serum free medium with or without hydrogen peroxide (Sigma-Aldrich,

UK) to a final concentration of 100  $\mu\text{M}$  and 200  $\mu\text{M}$  in 450  $\mu\text{l}$  of serum free medium. Hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) was used to induce oxidative stress [40] and the concentration and duration of  $\text{H}_2\text{O}_2$  treatments were determined through optimisation experiments and mirror previous studies in Tenon's ocular fibroblasts [41]; a 1-h exposure of 50  $\mu\text{M}$   $\text{H}_2\text{O}_2$  is considered physiological and 100–200  $\mu\text{M}$   $\text{H}_2\text{O}_2$  is deemed pathological [42,43]. Medium was then removed and the cells were washed twice with Seahorse medium (DMEM supplemented with 10 mM D-glucose (Sigma-Aldrich, UK), 2 mM L-glutamine (Sigma-Aldrich, UK) and 2 mM pyruvate (Sigma-Aldrich, UK), pH 7.4) prior to applying 450  $\mu\text{l}$  of seahorse medium as previously described [44]. The plates were then incubated at 37 °C with no  $\text{CO}_2$  for a further hour. XF Cell Mito Stress Test assays (Seahorse Bioscience, Agilent Technologies, UK) were performed to assess mitochondrial respiration through real-time, non-invasive measurement of oxygen consumption rate (OCR). The sequence of the Seahorse XF24 Mito Stress Test involves five measurements of the OCR at 7-min intervals, three measurements after addition of 1.26  $\mu\text{M}$  oligomycin (Sigma-Aldrich, UK), three measurements after addition of 1.0  $\mu\text{M}$  FCCP (Sigma-Aldrich, UK) and two final measurements after the addition of a combination of 1  $\mu\text{M}$  antimycin A (Sigma-Aldrich, UK) and 1  $\mu\text{M}$  rotenone (Sigma-Aldrich, UK). Within the assay empty wells were used as blanks and two wells had cells without the Mito Stress test reagents as a control. Six replicates were performed of each test condition and enabled the mitochondrial respiration parameters to be calculated, including basal respiration, ATP-linked respiration, proton leak respiration and spare capacity (see Supplement Fig. S1 and Table S1). The data was normalised by cell number using the CyQUANT Cell Proliferation Assay (Thermo Scientific, USA). For standardisation purposes, as the individual values per cell are small, these were then multiplied by  $1 \times 10^6$  and all the results from the Seahorse XF24 assay were presented in this manner [45].

The statistical analysis of the data was performed using GraphPad Prism 6.0 software (La Jolla, CA, USA). Additionally, linear mixed effect model was run in R [46]. This method of analysis was preferred as the analysis was performed on all data (120 data points from 20 subjects), while adjusting for correlation on measurements from same subjects, which was achieved by introducing a random intercept parameter for data that came from the same subject. This method of analysis pulls information from all variables into one model and hence has higher effective sample size to estimate the variability due to subject differences [47].

## 2.5. Measurement of oxidative stress

Tenons fibroblasts were tested for mitochondrial function changes using two probes: Mitosox Red (Thermo Fisher Scientific, USA) and CM-H2DCFDA (Thermo Fisher Scientific, USA). In order to perform these test the cells were prepared in a similar manner.  $8 \times 10^4$  cells Tenon's ocular fibroblasts were incubated with serum free medium at 37 °C with 5%  $\text{CO}_2$  and 95% humidity in an incubator for 24 h prior to testing.

MitoSOX™ Red (Thermo Fisher Scientific, USA) was used for detection of mitochondrial superoxide production. On the day of testing the medium was removed and washed twice with Hanks' Balanced Salt Solution (HBSS) (Gibco, Thermo Fisher Scientific, UK). Thereafter 5  $\mu\text{M}$  MitoSOX™ in HBSS was applied and incubated in the dark for 30 min. The cells were washed twice with HBSS, trypsinised and centrifuged at 1500RPM for 5 min. The pellet was washed with HBSS and centrifuged at 1500RPM for 5 min and resuspended in 500  $\mu\text{l}$  of HBSS and flow cytometry was performed.

CM-H2DCFDA (Thermo Fisher Scientific, USA) was used to measure intracellular reactive oxygen species (ROS). 5  $\mu\text{M}$  CM-H2DCFDA in phenol free and serum free DMEM/F12, (HEPES no phenol red) (Gibco, Thermo Fisher Scientific, UK) was applied and incubated in the dark for 30 min. The cells were washed twice with 1x phosphate-buffered-saline (PBS) (Gibco, Thermo Fisher Scientific, UK), trypsinised and centrifuged at 1500RPM for 5 min. The pellet was washed with PBS and centrifuged

at 1500RPM for 5 min and resuspended in 500  $\mu\text{l}$  of phenol free and serum free DMEM/F12, (HEPES no phenol red) and flow cytometry was performed.

Flow cytometry data was collected on the BD Accuri™ C6 Flow cytometer (BD Biosciences, USA) by collecting 5000 events and by setting an FSC-H threshold of 1,000,000. All experiments were performed in triplicate and statistical analysis of the data was performed using GraphPad Prism 6.0 software (La Jolla, CA, USA). Mann-Whitney U test was performed for each parameter.

## 3. Results

Primary Tenon's ocular fibroblasts (TFs) were cultured from POAG patients (GTFs;  $n = 10$ ) and disease negative non-glaucomatous controls (NTFs;  $n = 10$ ). All subjects were Caucasian and the POAG group were 70.03 (SD  $\pm 11.90$ ) years of age (mean ages ( $\pm$  standard deviation/SD) ( $n = 5$  female) and the control group were 78.30 (SD  $\pm 7.59$ ) years of age ( $n = 6$  female). The phenotypic data for each individual donor is given in Supplement Table S2. ( $n = 6$  had advanced glaucoma and  $n = 4$  had moderate glaucoma). There were no significant differences in the mitochondrial content of Tenon's ocular fibroblasts from disease negative non-glaucomatous and glaucomatous subjects as measured by citrate synthase activity (Fig. 1). This confirmed that the differences in subsequent experiments was not observed due to variations in mitochondrial content.

### 3.1. Impaired mitochondrial cellular bioenergetics in glaucomatous Tenon's ocular fibroblasts

The Mito Stress Test from the Seahorse XF24 Analyzer was used to investigate mitochondrial cellular bioenergetics in glaucomatous Tenon's ocular fibroblasts (GTFs) compared to non-glaucomatous Tenon's ocular fibroblasts (NTFs). An oxygen consumption rate (OCR) curve was generated from NTFs and GTFs obtained from POAG ( $n = 10$ ) and disease negative controls ( $n = 10$ ) and run in six replicates per subject (Fig. 2A) from which mitochondrial respiration parameters were calculated (Fig. 2B). Basal respiration is a measure of ATP synthase (ATP production) and proton leak. There was a significant reduction in basal respiration (basal OCR) between NTFs ( $3933 \pm 536$  pmol/min/ $10^6$  cells) compared to GTFs ( $2803 \pm 231$  pmol/min/ $10^6$  cells). Maximal respiration which is a measure of the maximum rate of respiration that the cell can achieve and was significantly reduced in GTFs ( $5617 \pm 463$  pmol/min/ $10^6$  cells) compared to NTFs ( $9163 \pm 1798$  pmol/min/ $10^6$





Fig. 1. The mitochondrial content measured by citrate synthase activity of glaucomatous Tenon's ocular fibroblasts (GTFs) and disease negative non-glaucomatous Tenon's ocular fibroblasts (NTFs). Citrate synthase is an exclusive marker of the mitochondrial matrix. There was no statistically significant difference ( $p = 0.3845$ ) in the citrate synthase activity assay between the GTFs and NTFs ( $n = 5$ ).




**Fig. 2.** The Seahorse XF Analyzer Mito Stress Test detected altered mitochondrial cellular bioenergetics in glaucomatous Tenon's ocular fibroblasts. (A) The oxygen consumption rate (OCR) curve of the Mito Stress Test in disease negative non-glaucomatous Tenon's ocular fibroblasts (NTFs) ( $n = 10$ ) and glaucomatous Tenon's ocular fibroblasts (GTFs) ( $n = 10$ ) after sequential addition of Oligo (oligomycin), FCCP and Rot/Ant A (rotenone/anti-mycin A) (mean of six replicates); (B) Calculation of the mitochondrial respiration parameters demonstrated a significant reduction of the basal respiration ( $p = 0.0449$ ), maximal respiration ( $p = 0.0113$ ) and spare capacity ( $p = 0.0481$ ). Data on the graph represents the mean  $\pm$  SEM (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ ).

cells). The spare capacity was also significantly reduced in GTFs ( $2813 \pm 354$  pmol/min/ $10^6$  cells) compared to NTFs ( $5230 \pm 1288$  pmol/min/ $10^6$  cells). The spare capacity describes the amount of additional ATP than can be generated by oxidative phosphorylation in the event of a sudden increase in energy demand or cell stress. The extracellular acidification rate was measured throughout the Mito Stress Test to calculate the baseline ECAR and ECAR oligomycin which reflects the glycolytic capacity. There was no significant difference in the ECAR in control fibroblasts compared to glaucoma. Overall, the reductions in basal and maximal respiration coupled with spare capacity defects highlights significant defects in mitochondrial bioenergetics in GTFs.

### 3.2. Oxidative stress and mitochondrial cellular bioenergetics in Tenon's ocular fibroblasts

Oxidative stress was induced by pre-treatment of  $H_2O_2$  at two concentrations (100  $\mu$ M and 200  $\mu$ M) for 1 h prior to the Mito Stress Test using the Seahorse XF24 Analyzer in NTFs and GTFs (Fig. 3 and Table 1). In both GTF and NTF, the basal respiration increased with exposure to 100  $\mu$ M  $H_2O_2$  but not 200  $\mu$ M  $H_2O_2$ . Mitochondrial basal respiration

responded to lower levels of oxidative stress but at higher levels of oxidative stress resulted in mitochondrial bioenergetic compromise. Proton leak increased at both 100  $\mu$ M and 200  $\mu$ M  $H_2O_2$  indicating mitochondrial damage due to increased uncoupling protein activity, damage to the inner mitochondrial membrane and/or electron transport chain complexes. In NTFs increasing concentrations of  $H_2O_2$  reduced the OCR curve with significant reductions in maximal respiration and spare capacity mirroring the findings in the GTFs without  $H_2O_2$  treatment (Fig. 3 and Table 1). These findings demonstrate increasing mitochondrial dysfunction in response to oxidative stress in NTFs with reduced cellular bioenergetics. This reflected the pre-treatment state of GTFs and the induction of further oxidative stress only impacted spare capacity in GTFs. Pre-treatment with 200  $\mu$ M  $H_2O_2$  significantly reduced spare capacity ( $1262 \pm 446$  pmol/min/ $10^6$  cells vs. from  $2813 \pm 354$  pmol/min/ $10^6$  cells) in GTFs (Fig. 3G.).  $H_2O_2$  induced oxidative stress further compromises spare capacity in GTFs hindering the cells already compromised ability to respond to cell stress. Given that mitochondrial cellular bioenergetics were already compromised in GTFs and the induction of oxidative stress resulted in similar OCR profiles in the NTFs while further impacting spare capacity in the GTFs we sought to



**Fig. 3.** Effect of hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) induced oxidative stress on mitochondrial cellular bioenergetics in Tenon's ocular fibroblasts. (A) The oxygen consumption rate (OCR) curve of the Mito Stress Test in disease negative non-glaucomatous Tenon's ocular fibroblasts (NTFs) ( $n = 10$ ) and glaucomatous Tenon's ocular fibroblasts (GTFs) ( $n = 10$ ) after sequential addition of Oligo (oligomycin), FCCP and Rot/Ant A (rotenone/antimycin A) (mean of six replicates). These graphs compare pre incubation with  $0 \mu\text{M}$   $\text{H}_2\text{O}_2$ ,  $100 \mu\text{M}$   $\text{H}_2\text{O}_2$  and  $200 \mu\text{M}$   $\text{H}_2\text{O}_2$  in A) control group B) glaucoma group. The mitochondrial respiration parameters were then calculated, and two-way ANOVA testing was performed to compare the differences. The respiration parameters include C) basal respiration, D) ATP production, E) proton leak, F) maximal respiration, G) spare capacity, H) non-mitochondrial respiration. The data shown is the mean  $\pm$  SEM. (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.005$ , \*\*\*\* =  $p < 0.0001$ ).

determine the basal oxidative stress in both GTFs and NTFs. The level of intracellular ROS was measured using a CM-H<sub>2</sub>DCFDA assay and a MitoSOX Red assay and in GTFs compared to NTFs there was a significant increase in general ROS in the cell, but no changes were observed in mitochondrial derived superoxide (Fig. 4). GTFs are already under oxidative stress prior to  $\text{H}_2\text{O}_2$  treatment which exacerbates already compromised mitochondrial bioenergetics.

#### 4. Discussion

The role of mitochondria in glaucoma pathogenesis has gained increasing interest as they are considered potential targets for therapeutic intervention [48–51]. In this study we have demonstrated impaired mitochondrial cellular bioenergetics in Tenon's ocular fibroblasts derived from glaucoma (POAG) patients. Furthermore, we have

shown elevated basal oxidative stress in GTFs compared to NTFs.  $\text{H}_2\text{O}_2$  induced ROS simulated the glaucomatous condition in NTFs and further compromised mitochondrial function in GTFs.

Using the Seahorse XF Mito Stress Test our study demonstrated that the mitochondrial respiration profile was globally impaired in GTFs compared to NTFs. Specifically, there were significant reductions in basal respiration, maximal respiration and the spare capacity in GTFs. A significant reduction in basal respiration has also been demonstrated in glaucoma lamina cribrosa cells [52]. The maximal respiration shows the maximum activity of electron transport chain and substrate oxidation that the cell can achieve. In GTFs the reduction in maximal respiration indicates a global defect in the electron transport chain and is a strong indicator of potential mitochondrial dysfunction [53]. Maximal respiration was reduced in blood lymphoblasts from POAG subjects [54] and complex I enzyme specific activity was significantly reduced by 18% in



**Table 1**

Post hoc Tukey's Multiple Comparison Testing to analyse the findings from the significant two-way ANOVA test of the mitochondrial respiration parameters after Seahorse XF Analyzer Mito Stress testing with or without hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in glaucomatous Tenon's ocular fibroblasts (GTFs) and disease negative non-glaucomatous Tenon's ocular fibroblasts (NTFs). Testing performed with 0  $\mu$ m H<sub>2</sub>O<sub>2</sub>, 100  $\mu$ m H<sub>2</sub>O<sub>2</sub>, and 200  $\mu$ m H<sub>2</sub>O<sub>2</sub> in 10 GTFs and 10 NTFs. This demonstrates that control fibroblasts exhibit a more significant response to H<sub>2</sub>O<sub>2</sub> than glaucoma fibroblasts (as shown by the response of the spare capacity and maximal respiration after pre incubation with H<sub>2</sub>O<sub>2</sub>. \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.005$ , \*\*\*\* =  $p < 0.0001$ ).


All results per 1 $\times$ 10 <sup>6</sup> cells	Basal Respiration		ATP Production		Proton Leak		Maximal Respiration		Spare Capacity		Non Mitochondrial Respiration	
	Significant	Adjusted p Value	Significant	Adjusted p Value	Significant	Adjusted p Value	Significant	Adjusted p Value	Significant	Adjusted p Value	Significant	Adjusted p Value
<b>Control</b>												
0 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 100 $\mu$ m H <sub>2</sub> O <sub>2</sub>	Yes**	0.0015	Yes****	<0.0001	Yes****	<0.0001	No	0.9576	Yes**	0.0031	Yes**	0.0067
0 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 200 $\mu$ m H <sub>2</sub> O <sub>2</sub>	No	0.2940	Yes****	<0.0001	Yes****	<0.0001	Yes**	0.0061	Yes****	<0.0001	No	0.9676
100 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 200 $\mu$ m H <sub>2</sub> O <sub>2</sub>	No	0.0710	No	0.2373	No	0.3052	Yes**	0.0029	Yes**	0.0085	Yes**	0.0034
<b>Glaucoma</b>												
0 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 100 $\mu$ m H <sub>2</sub> O <sub>2</sub>	Yes*	0.0136	Yes****	<0.0001	Yes****	<0.0001	No	0.8342	No	0.0795	Yes*	0.0193
0 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 200 $\mu$ m H <sub>2</sub> O <sub>2</sub>	No	0.3843	Yes****	<0.0001	Yes***	0.0001	No	0.2627	Yes**	0.0012	No	0.7626
100 $\mu$ m H <sub>2</sub> O <sub>2</sub> vs. 200 $\mu$ m H <sub>2</sub> O <sub>2</sub>	No	0.2379	No	0.6141	No	0.4621	No	0.0910	No	0.2419	No	0.0951

POAG lymphoblasts [55]. A significant reduction of maximal respiration has also been observed in other ocular age-related conditions (age related macular degeneration in RPE cells) using the Seahorse XF analyzer [56].

There was a significant reduction in spare capacity in ocular Tenon's fibroblasts from glaucoma patients. The spare capacity is a measure of the mitochondrial capacity to meet additional cellular energy requirements in response to cellular stress to avoid an ATP crisis [57]. In effect, spare capacity indicates how close a cell is to operating at its bioenergetic limit [53]. In this respect spare capacity is a measure of mitochondrial fitness, and low spare capacity reflects mitochondrial dysfunction which might not be apparent under basal conditions and has been reported in cardiovascular and chronic neurological diseases [58]. A significant reduction in spare capacity has also been demonstrated in human glaucoma lamina cribrosa cells from the optic nerve head [52]. Ocular Tenon's fibroblasts therefore mirror mitochondrial dysfunction in the optic nerve head and are therefore also likely to reflect altered mitochondrial bioenergetics in the optic nerve and RGCs in glaucoma. Patient derived cells, and specifically ocular cells, provide an excellent platform to assess mitochondrial dysfunction in glaucoma [19,25,28,34,35]. Tenon's ocular fibroblasts provide an accessible cell type to provide

enough material and case numbers for study and evaluate future metabolic and mitochondrial therapies in glaucoma.

Spare capacity depends on the functional integrity of the electron transport chain and the inner mitochondrial potential, the availability of energetic substrates for oxidation and the maintenance of mitochondrial homeostasis via biogenesis and mitophagy [57]. Oxidative stress has a significant impact on mitochondrial spare capacity [59,60]. Under conditions of oxidative stress, the spare capacity of cells is further depleted, and if the basal respiratory threshold is breached, cell death occurs [59–62]. Spare respiratory capacity levels correlate with the degree of mitochondrial plasticity, allowing bio-energetic adaptability in response to pathophysiological stress, and hence inadequate levels are associated with pathological conditions [57]. In GTFs there was elevated basal oxidative stress compared to NTFs which could represent one mechanism resulting in a reduced spare capacity. Oxidative stress and ageing can induce mitochondrial DNA (mtDNA) mutations impacting mitochondrial bioenergetics including spare capacity, in addition, to contributing to further ROS production [63]. Previous work by our group has demonstrated pathogenic variants in mtDNA extracted from peripheral blood leucocytes and Tenon's ocular fibroblasts from glaucoma patients [30,64]. The results demonstrate that the source of ROS in



**Fig. 4.** Measurement of intracellular reactive oxygen species in glaucomatous Tenon's ocular fibroblasts (GTFs) and disease negative non-glaucomatous Tenon's ocular fibroblasts (NTFs) was performed using A- MitoSOX Red assay to measure mitochondrial superoxide and B- CM- H<sub>2</sub>DCFDA to evaluate general reactive oxygen species. Oxidation of these probes by reactive oxygen species yields a fluorescent adduct. Measurement of mean fluorescence intensity of TFs using flow cytometry showed a significant increase in general reactive oxygen species in GTF (n = 5) compared to NTF (n = 5) but no significant difference in mitochondrial superoxide.

glaucomatous TFs is not mitochondrial in origin. In this paper we demonstrate elevated ROS and impaired mitochondrial bioenergetics in glaucoma, but the underlying mechanism of ROS induced mitochondrial dysfunction requires further investigation. The mechanistic basis is important to identify therapeutic strategies to reduce ROS, and mitigate impaired mitochondrial bioenergetics, to prevent or reduce RGC loss and protect vision in glaucoma. Several antioxidant-based therapies have been evaluated in experimental glaucoma models and clinical trials [65,66]. Coenzyme Q10 (ubiquinone) is a molecule that shuttles electrons from complex I and I to complex III which maintains the mitochondrial membrane potential, supporting ATP synthesis and inhibiting reactive oxygen species generation [67]. Improvements in retinal ganglion cell health following the topical administration of coenzyme Q10 have been demonstrated in rodent glaucoma models [67–70].

Neural tissue has significant energy demands and neurons can utilise 80% of their spare capacity to maintain ionic gradients and thus neuronal excitability [71,72]. This places neuronal function and survival vulnerable to mitochondrial dysfunction [73]. RGCs are extremely susceptible to mitochondrial compromise due to their marked bioenergetic requirements and morphology [16,17,51]. In the DBA/2J mouse model of glaucoma mitochondrial dysfunction is an early feature in the RGCs [74] and nicotinamide adenine dinucleotide (NAD) shows an age-dependent decline contributing to mitochondrial dysfunction and vulnerability to glaucoma in this model [51,74,75]. The prevention of NAD decline by dietary supplementation with nicotinamide (NAM; the amide form of vitamin B3) protected against mitochondrial and metabolic dysfunction and so RGC neurodegeneration in the DBA/2J glaucoma mouse model [51,76]. Recent human studies with oral nicotinamide supplementation with or without pyruvate have shown short term beneficial effects [77,78].

## 5. Conclusions

Bioenergetic based therapies in glaucoma face several challenges including the chronic nature of glaucoma, the clinical variability in disease progression and determining robust primary endpoints [51,79]. We have used Tenon's ocular fibroblasts derived from glaucoma (POAG) patients to detect elevated basal ROS levels and altered mitochondrial bioenergetics. This approach provides important insight into the pathogenesis of glaucoma but also could be employed as a strategy to risk

profile patients for future bioenergetic based neuroprotection trials in glaucoma.

## Funding

This work was supported by Glaucoma UK (formerly known as International Glaucoma Association), Fight for Sight (UK), and the Royal Liverpool University Hospital Charitable Funds.

## Declaration of competing interest

No competing interest or conflict of interest to declare.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.freeradbiomed.2022.07.009>.

## References

- [1] G.Y.X. Kong, N.J. Van Bergen, I.A. Trounce, J.G. Crowston, Mitochondrial dysfunction and glaucoma, *J. Glaucoma* 18 (2009) 93–100, <https://doi.org/10.1097/JG.0b013e318181284f>.
- [2] R.N. Weinreb, P.T. Khaw, Primary open-angle glaucoma, *Lancet* 363 (2004) 1711–1720, [https://doi.org/10.1016/S0140-6736\(04\)16257-0](https://doi.org/10.1016/S0140-6736(04)16257-0).
- [3] H.A. Quigley, A.T. Broman, The number of people with glaucoma worldwide in 2010 and 2020, *Br. J. Ophthalmol.* 90 (2006) 262–267, <https://doi.org/10.1136/bjo.2005.081224>.
- [4] J.B. Jonas, T. Aung, R.R. Bourne, A.M. Bron, R. Ritch, S. Panda-Jonas, Glaucoma, *Lancet* 390 (2017) 2183–2193, [https://doi.org/10.1016/S0140-6736\(17\)31469-1](https://doi.org/10.1016/S0140-6736(17)31469-1).
- [5] S. Alqawlaq, J.G. Flanagan, J.M. Sivak, All roads lead to glaucoma: induced retinal injury cascades contribute to a common neurodegenerative outcome, *Exp. Eye Res.* 183 (2019) 88–97, <https://doi.org/10.1016/j.exer.2018.11.005>.
- [6] G. Tezel, Multifactorial pathogenic processes of retinal ganglion cell degeneration in glaucoma towards multi-target strategies for broader treatment effects, *Cells* 10 (2021), <https://doi.org/10.3390/cells10061372>.
- [7] R. Wormald, G. Virgili, A. Azuara-Blanco, Systematic reviews and randomised controlled trials on open angle glaucoma, *Eye (Basingstoke)* 34 (2020) 161–167, <https://doi.org/10.1038/s41433-019-0687-5>.
- [8] D. Peters, B. Bengtsson, A. Heijl, Lifetime risk of blindness in open-angle glaucoma, *Am. J. Ophthalmol.* 156 (2013), <https://doi.org/10.1016/j.ajo.2013.05.027>.
- [9] A. Heijl, M.C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, M. Hussein, Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial, *Arch. Ophthalmol.* 120 (2002), <https://doi.org/10.1001/archophth.120.10.1268>.

- [10] S. Drance, D.R. Anderson, M. Schulzer, Risk factors for progression of visual field abnormalities in normal-tension glaucoma, *Am. J. Ophthalmol.* 131 (2001) 699–708, [https://doi.org/10.1016/S0002-9334\(01\)00964-3](https://doi.org/10.1016/S0002-9334(01)00964-3).
- [11] K. Nouri-Mahdavi, D. Hoffman, A.L. Coleman, G. Liu, G. Li, D. Gaasterland, J. Caprioli, Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study, *Ophthalmology* 111 (2004), <https://doi.org/10.1016/j.ophtha.2004.02.017>.
- [12] B.E.K. Klein, R. Klein, W.E. Sponsel, T. Franke, L.B. Cantor, J. Martone, M. J. Menage, Prevalence of glaucoma: the beaver dam eye study, *Ophthalmology* 99 (1992) 1499–1504, [https://doi.org/10.1016/S0161-6420\(92\)31774-9](https://doi.org/10.1016/S0161-6420(92)31774-9).
- [13] P. Mitchell, W. Smith, K. Attebo, P.R. Healey, Prevalence of open-angle glaucoma in Australia: the blue mountains eye study, *Ophthalmology* 103 (1996) 1661–1669, [https://doi.org/10.1016/S0161-6420\(96\)30449-1](https://doi.org/10.1016/S0161-6420(96)30449-1).
- [14] M.C. Leske, A. Heijl, L. Hyman, B. Bengtsson, L. Dong, Z. Yang, Predictors of long-term progression in the early manifest glaucoma trial, *Ophthalmology* 114 (2007) 1965–1972, <https://doi.org/10.1016/j.ophtha.2007.03.016>.
- [15] A. Jurcau, Insights into the pathogenesis of neurodegenerative diseases: focus on mitochondrial dysfunction and oxidative stress, *Int. J. Mol. Sci.* 22 (2021), <https://doi.org/10.3390/ijms222111847>.
- [16] N.A. Muench, S. Patel, M.E. Maes, R.J. Donahue, A. Ikeda, R.W. Nickells, The influence of mitochondrial dynamics and function on retinal ganglion cell susceptibility in optic nerve disease, *Cells* 10 (2021) 1593, <https://doi.org/10.3390/cells10071593>.
- [17] Y.A. Ito, A. Di Polo, Mitochondrial dynamics, transport, and quality control: a bottleneck for retinal ganglion cell viability in optic neuropathies, *Mitochondrion* 36 (2017) 186–192, <https://doi.org/10.1016/j.mito.2017.08.014>.
- [18] N.N. Osborne, Pathogenesis of ganglion “cell death” in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria, *Prog. Brain Res.* 173 (2008), [https://doi.org/10.1016/S0079-6123\(08\)01124-2](https://doi.org/10.1016/S0079-6123(08)01124-2).
- [19] J.R. Tribble, A. Vasalauskaitė, T. Redmond, R.D. Young, S. Hassan, M.P. Fautsch, F. Sengpiel, P.A. Williams, J.E. Morgan, Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma, *Brain Commun.* 1 (2019), <https://doi.org/10.1093/braincomms/fcz035>.
- [20] P.A. Williams, J.M. Harder, N.E. Foxworth, K.E. Cochran, V.M. Philip, V. Porciatti, O. Smithies, S.W.M. John, Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice, *Science* 355 (2017) 756–760, <https://doi.org/10.1126/science.aal0092>, 1979.
- [21] S. Baltan, D.M. Inman, C.A. Danilov, R.S. Morrison, D.J. Calkins, P.J. Horner, Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration, *J. Neurosci.* 30 (2010) 5644–5652, <https://doi.org/10.1523/JNEUROSCI.5956-09.2010>.
- [22] M.J. Gilhooly, N. Owen, M. Moosajee, P.Y.W. Man, From transcriptomics to treatment in inherited optic neuropathies, *Genes* 12 (2021) 1–15, <https://doi.org/10.3390/genes12020147>.
- [23] N.J. van Bergen, J.G. Crowston, J.E. Craig, K.P. Burdon, L.S. Kearns, S. Sharma, A. W. Hewitt, D.A. Mackey, I.A. Truncione, Measurement of systemic mitochondrial function in advanced Primary Open-Angle Glaucoma and leber hereditary optic neuropathy, *PLoS One* 10 (2015), <https://doi.org/10.1371/journal.pone.0140919>.
- [24] J.G. Crowston, Oxidative stress and mitochondrial dysfunction in glaucoma § vicki chrysostomou , fatemeh rezania , ian a trounce and, *Curr. Opin. Pharmacol.* 13 (2013) 12–15, <https://doi.org/10.1016/j.coph.2012.09.008>.
- [25] K. Kamel, C.J. O'Brien, A.v. Zhdanov, D.B. Papkovsky, A.F. Clark, W.D. Stamer, M. Irnaten, Reduced oxidative phosphorylation and increased glycolysis in human glaucoma lamina cribrosa cells, *Invest. Ophthalmol. Vis. Sci.* 61 (2020) 4, <https://doi.org/10.1167/iov.61.13.4>.
- [26] G. Lascaratos, D.F. Garway-Heath, C.E. Willoughby, K.-Y. Chau, A.H.V. v Schapira, Mitochondrial dysfunction in glaucoma: understanding genetic influences, *Mitochondrion* 12 (2012) 202–212, <https://doi.org/10.1016/j.mito.2011.11.004>.
- [27] G. Lascaratos, K.-Y. Chau, H. Zhu, D. Gkotsi, R. King, I. Gout, D. Kamal, P. J. Luthert, A.H.V. Schapira, D.F. Garway-Heath, Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency, *Neurobiol. Dis.* 82 (2015) 78–85, <https://doi.org/10.1016/j.NBD.2015.05.012>.
- [28] A. Izzotti, M. Longobardi, C. Cartiglia, S.C. Sacca, Mitochondrial damage in the trabecular meshwork occurs only in primary open-angle glaucoma and in pseudoexfoliative glaucoma, *PLoS One* 6 (2011), e14567, <https://doi.org/10.1371/journal.pone.0014567>.
- [29] D. Banerjee, A. Banerjee, S. Mookherjee, M. Vishal, A. Mukhopadhyay, A. Sen, A. Basu, K. Ray, Mitochondrial genome analysis of primary open angle glaucoma patients, *PLoS One* 8 (2013), <https://doi.org/10.1371/journal.pone.0070760>.
- [30] P. Sundaresan, D.A. Simpson, C. Sambare, S. Duffy, J. Lechner, A. Dastane, E. W. Dervan, N. Vallabh, V. Chelkerkar, M. Deshpande, C. O'Brien, A.J. McKnight, C. E. Willoughby, Whole-mitochondrial genome sequencing in primary open-angle glaucoma using massively parallel sequencing identifies novel and known pathogenic variants, *Genet. Med.* 17 (2015), <https://doi.org/10.1038/gim.2014.121>.
- [31] K.K. Abu-Amero, J. Morales, T.M. Bosley, Mitochondrial abnormalities in patients with primary open-angle glaucoma, *Invest. Ophthalmol. Vis. Sci.* 47 (2006) 2533–2541, <https://doi.org/10.1167/iov.05-1639>.
- [32] S. Lee, L. Sheek, J.G. Crowston, N.J. van Bergen, E.C. O'Neill, F. O'Hare, Y.X. G. Kong, V. Chrysostomou, A.L. Vincent, I.A. Truncione, Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts, *Investig. Ophthalmol. Vis. Sci.* 53 (2012) 2431–2437, <https://doi.org/10.1167/iov.12-9596>.
- [33] A. Izzotti, S.C. Sacca, M. Longobardi, C. Cartiglia, Mitochondrial damage in the trabecular meshwork of patients with glaucoma, *Arch. Ophthalmol.* 128 (2010), <https://doi.org/10.1001/archophthol.128.10.87>.
- [34] Y. He, K.W. Leung, Y.-H. Zhang, S. Duan, X.-F. Zhong, R.-Z. Jiang, Z. Peng, J. Tombran-Tink, J. Ge, Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants, *Invest. Ophthalmol. Vis. Sci.* 49 (2008) 1447, <https://doi.org/10.1167/iov.07-1361>.
- [35] A. Want, S.R. Gillespie, Z. Wang, R. Gordon, C. Iomini, R. Ritch, J.M. Wolosin, A. M. Bernstein, Autophagy and mitochondrial dysfunction in tenon fibroblasts from exfoliation glaucoma patients, *PLoS One* 11 (2016), <https://doi.org/10.1371/journal.pone.0157404>.
- [36] J. Wang, C. Jiang, Q. Jing, Y. Jiang, T. Shao, Differential effects of TGF-β2 on the low-density lipoprotein receptor expression in three types of human subconjunctival fibroblasts, *Curr. Eye Res.* 46 (2021) 35–44, <https://doi.org/10.1080/02713683.2020.1789174>.
- [37] P. Brusini, S. Filacorda, Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma, *J. Glaucoma* 15 (2006) 40–46, <https://doi.org/10.1097/01.jgg.0000195932.48288.97>.
- [38] E. De Falco, G. Scafetta, C. Napoletano, R. Puca, E.M. Vingolo, G. Ragona, O. Iorio, G. Frati, A standardized laboratory and surgical method for in vitro culture isolation and expansion of primary human Tenon's fibroblasts, *Cell Tissue Bank.* 14 (2013) 277–287, <https://doi.org/10.1007/s10561-012-9325-1>.
- [39] F.J.M. Van Kuppeveld, K.E. Johansson, J.M.D. Galama, J. Kissing, G. Bolske, J.T. M. Van der Logt, W.J.G. Melchers, Detection of mycoplasma contamination in cell cultures by a mycoplasma group-specific PCR, *Appl. Environ. Microbiol.* 60 (1994) 149–152, 0099-2240/94.
- [40] C. Ransy, C. Vaz, A. Lombès, F. Bouillaud, Use of H2O2 to cause oxidative stress, the catalase issue, *Int. J. Mol. Sci.* 21 (2020), <https://doi.org/10.3390/ijms21239149>.
- [41] C.C. Tsai, S.B. Wu, P.C. Chang, Y.H. Wei, Alteration of Connective Tissue Growth Factor (CTGF) expression in orbital fibroblasts from patients with graves' ophthalmopathy, *PLoS One* 10 (2015), <https://doi.org/10.1371/journal.pone.0143514>.
- [42] M. Chwa, S.R. Atilano, V. Reddy, N. Jordan, D.W. Kim, M.C. Kenney, Increased stress-induced generation of reactive oxygen species and apoptosis in human keratoconus fibroblasts, *Invest. Ophthalmol. Vis. Sci.* 47 (2006) 1902, <https://doi.org/10.1167/iov.05-0828>.
- [43] X. Wang, J.W. Simpkins, J.A. Dykens, P.R. Cammarata, Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability, *Invest. Ophthalmol. Vis. Sci.* 44 (2003) 2067, <https://doi.org/10.1167/iov.02-0841>.
- [44] D.A. Ferrington, M.C. Ebeling, R.J. Kapphahn, M.R. Terluk, C.R. Fisher, J. R. Polanco, H. Roehrich, M.M. Leary, Z. Geng, J.R. Dutton, S.R. Montezuma, Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration, *Redox Biol.* 13 (2017) 255–265, <https://doi.org/10.1016/j.redox.2017.05.015>.
- [45] F. Ye, C.L. Hoppel, Measuring oxidative phosphorylation in human skin fibroblasts, *Anal. Biochem.* 437 (2013) 52–58, <https://doi.org/10.1016/j.ab.2013.02.010>.
- [46] R Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2019.
- [47] A. Galecki, T. Burzykowski, Linear Mixed-Effects Models Using R: Step by Step Analysis, 2013.
- [48] D.C. Wallace, W. Fan, V. Proccaccio, Mitochondrial energetics and therapeutics, *Annu. Rev. Pathol.* 5 (2010) 297–348, <https://doi.org/10.1146/annurev.pathol.4.110807.092314>.
- [49] A. Martucci, C. Nucci, Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma, *Neural Regen. Res.* 14 (2019) 197–200, <https://doi.org/10.4103/1673-5374.244781>.
- [50] F. Hui, J. Tang, P.A. Williams, M.B. McGuinness, X. Hadoux, R.J. Casson, M. Coote, I.A. Truncione, K.R. Martin, P. van Wijngaarden, J.G. Crowston, Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial, *Clin. Exp. Ophthalmol.* 48 (2020) 903–914, <https://doi.org/10.1111/ceo.13818>.
- [51] R.J. Casson, G. Chidlow, J.G. Crowston, P.A. Williams, J.P.M. Wood, Retinal energy metabolism in health and glaucoma, *Prog. Retin. Eye Res.* 81 (2021), 100881, <https://doi.org/10.1016/j.preteyeres.2020.100881>.
- [52] K. Kamel, C.J. O'Brien, A.v. Zhdanov, D.B. Papkovsky, A.F. Clark, D. Stamer, M. Irnaten, Reduced oxidative phosphorylation and increased glycolysis in human glaucoma lamina cribrosa cells, *Investig. Ophthalmol. Vis. Sci.* 61 (2020), <https://doi.org/10.1167/IOVS.61.13.4>.
- [53] M.D. Brand, D.G. Nicholls, Assessing mitochondrial dysfunction in cells, *Biochem. J.* 435 (2011) 297–312, <https://doi.org/10.1042/BJ20110162>.
- [54] S. Lee, L. Sheek, J.G. Crowston, N.J. van Bergen, E.C. O'Neill, F. O'Hare, Y.X. G. Kong, V. Chrysostomou, A.L. Vincent, I.A. Truncione, Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts, *Investig. Ophthalmol. Vis. Sci.* 53 (2012) 2431–2437, <https://doi.org/10.1167/iov.12-9596>.
- [55] N.J. van Bergen, J.G. Crowston, L.S. Kearns, S.E. Staffieri, A.W. Hewitt, A.C. Cohn, D.A. Mackey, I.A. Truncione, Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy, *PLoS One* 6 (2011), <https://doi.org/10.1371/journal.pone.0021347>.
- [56] D.A. Ferrington, M.C. Ebeling, R.J. Kapphahn, M.R. Terluk, C.R. Fisher, J. R. Polanco, H. Roehrich, M.M. Leary, Z. Geng, J.R. Dutton, S.R. Montezuma, Altered bioenergetics and enhanced resistance to oxidative stress in human retinal



- pigment epithelial cells from donors with age-related macular degeneration, *Redox Biol.* 13 (2017) 255–265, <https://doi.org/10.1016/j.redox.2017.05.015>.
- [57] P. Marchetti, Q. Fovez, N. Germain, R. Khamari, J. Kluza, Mitochondrial spare respiratory capacity: mechanisms, regulation, and significance in non-transformed and cancer cells, *FASEB (Fed. Am. Soc. Exp. Biol.) J.* 34 (2020), <https://doi.org/10.1096/fj.202000767R>.
- [58] D.G. Nicholls, Spare respiratory capacity, oxidative stress and excitotoxicity, *Biochem. Soc. Trans.* 37 (2009), <https://doi.org/10.1042/BST0371385>.
- [59] B.P. Dranka, G.A. Benavides, A.R. Diers, S. Giordano, B.R. Zelikson, C. Reily, L. Zou, J.C. Chatham, B.G. Hill, J. Zhang, A. Landar, V.M. Darley-Usmar, Assessing bioenergetic function in response to oxidative stress by metabolic profiling, *Free Radic. Biol. Med.* 51 (2011), <https://doi.org/10.1016/j.freeradbiomed.2011.08.005>.
- [60] J.A. Armstrong, N.J. Cash, Y. Ouyang, J.C. Morton, M. Chvanov, D. Latawiec, M. Awais, A.v. Tepikin, R. Sutton, D.N. Criddle, Oxidative stress alters mitochondrial bioenergetics and modifies pancreatic cell death independently of cyclophilin D, resulting in an apoptosis-to-necrosis shift, *J. Biol. Chem.* 293 (2018), <https://doi.org/10.1074/jbc.RA118.003200>.
- [61] B.E. Sansbury, S.P. Jones, D.W. Riggs, V.M. Darley-Usmar, B.G. Hill, Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation, in: *Chemico-Biological Interactions*, 2011, <https://doi.org/10.1016/j.cbi.2010.12.002>.
- [62] B.P. Dranka, B.G. Hill, V.M. Darley-Usmar, Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species, *Free Radic. Biol. Med.* 48 (2010), <https://doi.org/10.1016/j.freeradbiomed.2010.01.015>.
- [63] C. Desler, T.L. Hansen, J.B. Frederiksen, M.L. Marcker, K.K. Singh, L. Juel Rasmussen, Is there a link between mitochondrial reserve respiratory capacity and aging? *J. Aging Res.* (2012) 2012, <https://doi.org/10.1155/2012/192503>.
- [64] N.A. Vallabh, B. Lane, D.A. Simpson, M. Fuchs, A. Choudhary, D. Criddle, R. Cheeseman, C. Willoughby, Evidence of somatic mitochondrial DNA mutations in primary open angle glaucoma, *Investig. Ophthalmol. Vis. Sci.* 60 (2019) 1613.
- [65] J.J. Garcia-Medina, E. Rubio-Velazquez, M.D. Lopez-Bernal, A. Cobo-Martinez, V. Zanon-Moreno, M.D. Pinazo-Duran, M. Del-Rio-Vellosillo, Glaucoma and antioxidants: review and update, *Antioxidants* 9 (2020), <https://doi.org/10.3390/antiox9111031>.
- [66] C. Harada, T. Noro, A. Kimura, X. Guo, K. Namekata, T. Nakano, T. Harada, Suppression of oxidative stress as potential therapeutic approach for normal tension glaucoma, *Antioxidants* 9 (2020), <https://doi.org/10.3390/antiox9090874>.
- [67] D. Lee, M.S. Shim, K.Y. Kim, Y.H. Noh, H. Kim, S.Y. Kim, R.N. Weinreb, W.K. Ju, Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma, *Investig. Ophthalmol. Vis. Sci.* 55 (2014) 993–1005, <https://doi.org/10.1167/iov.13-12564>.
- [68] C. Nucci, R. Tartaglione, A. Cerulli, R. Mancino, A. Spanò, F. Cavaliere, L. Rombolà, G. Bagetta, M.T. Corasaniti, L.A. Morrone, Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat, *Int. Rev. Neurobiol.* (2007), [https://doi.org/10.1016/S0074-7742\(07\)82022-8](https://doi.org/10.1016/S0074-7742(07)82022-8).
- [69] B.M. Davis, K. Tian, M. Pahlitzsch, J. Brenton, N. Ravindran, G. Butt, G. Malaguarnera, E.M. Normando, L. Guo, M.F. Cordeiro, Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension, *Mitochondrion* (2017), <https://doi.org/10.1016/j.mito.2017.05.010>.
- [70] M. Lulli, E. Witort, L. Papucci, E. Torre, C. Schipani, C. Bergamini, M.D. Monte, S. Capaccioli, Coenzyme Q10 instilled as eye drops on the cornea reaches the retina and protects retinal layers from apoptosis in a mouse model of kainate-induced retinal damage, *Investig. Ophthalmol. Vis. Sci.* (2012), <https://doi.org/10.1167/iov.12-10374>.
- [71] D.G. Nicholls, Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease, *Int. J. Biochem. Cell Biol.* 34 (2002), [https://doi.org/10.1016/S1357-2725\(02\)00077-8](https://doi.org/10.1016/S1357-2725(02)00077-8).
- [72] O. Kann, R. Kovács, Mitochondria and neuronal activity, *Am. J. Physiol. Cell Physiol.* 292 (2007), <https://doi.org/10.1152/ajpcell.00222.2006>.
- [73] D. Trigo, C. Avelar, M. Fernandes, S. Juliana, O. da Cruz e Silva, Mitochondria, energy, and metabolism in neuronal health and disease, *FEBS (Fed. Eur. Biochem. Soc.) Lett.* (2022), <https://doi.org/10.1002/1873-3468.14298> n/a.
- [74] P.A. Williams, J.M. Harder, N.E. Foxworth, K.E. Cochran, V.M. Philip, V. Porciatti, O. Smithies, S.W.M. John, Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice, *Science* (2017) 355, <https://doi.org/10.1126/science.aal0092>, 1979.
- [75] P.A. Williams, J.M. Harder, B.H. Cardozo, N.E. Foxworth, S.W.M. John, Nicotinamide treatment robustly protects from inherited mouse glaucoma, *Commun. Integr. Biol.* 11 (2018), <https://doi.org/10.1080/19420889.2017.1356956>.
- [76] J.R. Tribble, A. Otmami, S. Sun, S.A. Ellis, G. Cimaglia, R. Vohra, M. Jõe, E. Lardner, A.P. Venkataraman, A. Domínguez-Vicent, E. Kokkali, S. Rho, G. Jóhannesson, R. W. Burgess, P.G. Fuerst, R. Brautaset, M. Kolko, J.E. Morgan, J.G. Crowston, M. Votruba, P.A. Williams, Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction, *Redox Biol.* 43 (2021), <https://doi.org/10.1016/j.redox.2021.101988>.
- [77] C.G. de Moraes, S.W.M. John, P.A. Williams, D.M. Blumberg, G.A. Cioffi, J. M. Liebmann, Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial, *JAMA Ophthalmology* 140 (2022), <https://doi.org/10.1001/jamaophthalmol.2021.4576>.
- [78] F. Hui, J. Tang, P.A. Williams, M.B. McGuinness, X. Hadoux, R.J. Casson, M. Coote, I.A. Trounce, K.R. Martin, P. Wijngaarden, J.G. Crowston, Improvement in inner retinal function in glaucoma with nicotinamide (vitamin <sc>B3</sc>) supplementation: a crossover randomized clinical trial, *Clin. Exp. Ophthalmol.* 48 (2020) 903–914, <https://doi.org/10.1111/ceo.13818>.
- [79] L. Storgaard, T.L. Tran, J.C. Freiberg, A.S. Hauser, M. Kolko, Glaucoma clinical Research: trends in treatment strategies and drug development, *Front. Med.* 8 (2021), <https://doi.org/10.3389/fmed.2021.733080>.